ACE-031
Myostatin pathway inhibition
Muscle Growthsubcutaneousany
Overview
Myostatin inhibitor that promotes muscle growth by blocking the myostatin pathway. Originally developed for muscular dystrophy.
Dosing
- Typical Dosage
- 0.5-1 mg/kg
- Frequency
- Every 2 weeks
- Cycle Duration
- 8-12 weeks
- Administration
- subcutaneous
Available Vial Sizes
1mg
Research compound. May cause nosebleeds and gum bleeding.
Comprehensive Information
AI-GeneratedGenerating comprehensive analysis...
This may take a moment
Mechanism of Action
Key Benefits
Optimal Timing
Potential Side Effects
Stacking Suggestions
Practical Tips
Could not load AI-generated information
Track Your ACE-031 Protocol
Join UpgradeYourself to track your peptide protocols, log injections with our interactive body map, and receive AI-powered insights tailored to your health goals.
Free forever planNo credit card required100+ peptides tracked